

Anti-emetics and Leuprolide acetate prior authorization requirements

Refer to the Oxford injectable cancer therapy prior authorization notice in the [May 2021 Network Bulletin](#) for further information.

Effective Date: Aug. 1, 2021

Applicable codes

Effective Aug. 1, 2021, prior authorization will be required for the following 8 anti-emetics codes and leuprolide acetate for UnitedHealthcare Oxford members with a cancer diagnosis.

HCPCS code	Description
J0185	Injection, aprepitant, 1 mg
J1453	Injection, fosaprepitant, 1 mg
J1454	Injection, fosnetupitant 235 mg and palonosetron, 0.25 mg
J1627	Injection, granisetron, extended-release, 0.1 mg
J1950	Leuprolide acetate
J2469	Injection, palonosetronHCl, 25 mcg
J8501	Aprepitant, oral, 5 mg
J8670	Rolapitant, oral, 1 mg
J8655	Netupitant 300 mg and palonosetron 0.5 mg, oral